Sections
| Title | Starting Page | Number of Pages |
|---|
| By 2016, the Global Vaccines Market is Expected to Generate More Than Twice the Annual Revenue of 2009 | 1 | 1 |
| The Vaccines Industry is Looking to Increase its Revenues Through the Introduction of Novel Vaccines and Indication Expansions for Established Products | 1 | 1 |
| Licensing and Alliance Agreements Accounted for 81% of the M&A and Licensing Landscape | 2 | 1 |
| 1 Table of Contents | 3 | 5 |
| List of Figures | 6 | 2 |
| 2 Introduction | 8 | 1 |
| 3 GBI Research Report Guidance | 9 | 1 |
| 4 The Future of Global Vaccines : Market Overview | 10 | 2 |
| Vaccine Preventable Diseases | 10 | 1 |
| 4.2 Vaccine Manufacturing Process | 10 | 2 |
| 5 The Future of Global Vaccines: Global Vaccines Market | 12 | 12 |
| 5.1 Market Forecasts | 12 | 1 |
| 5.1.1 Market Share by Disease Sectors | 13 | 1 |
| 5.1.2 Market Share by Geography | 14 | 1 |
| 5.2 Average Cost of Vaccination per Child | 14 | 1 |
| 5.3 Target Population | 15 | 2 |
| 5.3.1 Immunization Coverage | 17 | 2 |
| 5.4 Unmet Needs | 19 | 1 |
| 5.5 Market Trends | 20 | 1 |
| 5.5.1 Immunization Programs | 20 | 1 |
| 5.5.2 Public-Private Partnerships | 20 | 1 |
| 5.5.3 Production Capacity | 20 | 1 |
| 5.5.4 Reimbursements | 20 | 1 |
| 5.6 Drivers | 21 | 1 |
| 5.6.1 Growth will be Driven by Vaccines Targeting New Diseases | 21 | 1 |
| Adult Vaccines Segment will Provide Significant Boost to Growth of the Market | 21 | 1 |
| 5.6.3 Pediatric Combination Vaccines will Continue to Drive Growth | 22 | 1 |
| 5.6.4 Availability of Vaccine Technologies That Help Increase Efficacy and Safety will Drive Innovation and Growth | 22 | 1 |
| 5.6.5 Cancer and HIV/AIDS Vaccines Hold Significant Potential for the Future | 22 | 1 |
| 5.7 Barriers | 22 | 1 |
| 5.7.1 Limitations in Production Capacity Delays Realization of Potential | 22 | 1 |
| 5.7.2 High Initial Capital Investments and Technical Expertise Acts as Entry Barrier | 22 | 1 |
| 5.7.3 Lack of Harmonized Regulations Delays Vaccine Launch and Acceptance | 23 | 1 |
| 6 The Future of Global Vaccines: The US Vaccines Market | 24 | 6 |
| Market Overview | 24 | 1 |
| 6.2 Market Forecasts | 24 | 1 |
| 6.3 Average Cost of Vaccination per Child | 25 | 1 |
| 6.4 Immunization Schedule | 26 | 1 |
| 6.5 Regulatory Framework | 26 | 2 |
| 6.6 Vaccine Procurement | 28 | 1 |
| 6.7 Vaccine Stockpiling | 28 | 2 |
| 7 The Future of Global Vaccines: European Vaccines Market | 30 | 11 |
| 7.1 Market Overview | 30 | 1 |
| 7.2 Market Forecasts | 30 | 1 |
| 7.3 Average Cost of Vaccination per Child | 31 | 1 |
| 7.4 Vaccine Stockpiling | 32 | 1 |
| 7.5 The United Kingdom | 33 | 1 |
| 7.5.1 Immunization Schedule | 33 | 1 |
| 7.5.2 Regulatory Framework | 33 | 1 |
| 7.5.3 Vaccine Procurement | 33 | 1 |
| 7.6 France | 34 | 1 |
| 7.6.1 Immunization Schedule | 34 | 1 |
| 7.6.2 Regulatory Framework | 34 | 2 |
| 7.6.3 Vaccine Procurement | 36 | 1 |
| 7.7 Germany | 36 | 1 |
| 7.7.1 Immunization Schedule | 36 | 1 |
| 7.7.2 Regulatory Framework | 36 | 1 |
| 7.7.3 Vaccine Procurement | 37 | 1 |
| 7.8 Italy | 38 | 1 |
| 7.8.1 Immunization Schedule | 38 | 1 |
| 7.8.2 Regulatory Framework | 38 | 1 |
| 7.8.3 Vaccine Procurement | 39 | 1 |
| 7.9 Spain | 39 | 1 |
| 7.9.1 Immunization Schedule | 39 | 1 |
| 7.9.2 Regulatory Framework | 39 | 1 |
| 7.9.3 Vaccine Procurement | 40 | 1 |
| 8 The Future of Global Vaccines: Rest of the World | 41 | 3 |
| 8.1 Market Overview | 41 | 1 |
| 8.2 Market Forecasts | 41 | 1 |
| 8.3 Average Cost of Vaccination per Child | 41 | 1 |
| 8.4 Immunization Schedule | 42 | 1 |
| 8.5 Regulatory Framework | 42 | 1 |
| 8.6 Vaccine Procurement | 43 | 1 |
| 8.7 Vaccine Stockpiling | 43 | 1 |
| 9 The Future of Global Vaccines: Global Rotavirus Vaccines Market | 44 | 5 |
| 9.1 Market Overview | 44 | 1 |
| 9.2 Market Forecasts | 44 | 1 |
| 9.3 Average Cost of Vaccination | 45 | 1 |
| 9.4 Target Population | 46 | 1 |
| 9.4.1 Immunization Coverage | 46 | 1 |
| 9.5 Product Analysis | 47 | 1 |
| 9.5.1 RotaTeq | 47 | 1 |
| 9.5.1.1 Overview | 47 | 1 |
| 9.5.1.2 Indications | 47 | 1 |
| 9.5.1.3 Mechanism of action | 47 | 1 |
| 9.5.1.4 Dosage | 47 | 1 |
| 9.5.2 Rotarix | 47 | 1 |
| 9.5.2.1 Overview | 47 | 1 |
| 9.5.2.2 Indications | 48 | 1 |
| 9.5.2.3 Mechanism of action | 48 | 1 |
| 9.5.2.4 Dosage | 48 | 1 |
| 9.6 Vaccine Pipeline Analysis | 48 | 1 |
| 10 The Future of Global Vaccines: Global Pneumococcal Vaccines Market | 49 | 5 |
| 10.1 Market Overview | 49 | 1 |
| 10.2 Market Forecasts | 49 | 1 |
| 10.3 Average Cost of Vaccination | 50 | 1 |
| 10.4 Target Population | 51 | 1 |
| 10.4.1 Immunization Coverage | 51 | 1 |
| 10.5 Product Analysis | 52 | 1 |
| 10.5.1 Prevnar | 52 | 1 |
| 10.5.1.1 Overview | 52 | 1 |
| 10.5.1.2 Indications | 52 | 1 |
| 10.5.1.3 Mechanism of Action | 52 | 1 |
| 10.5.1.4 Dosage | 52 | 1 |
| 10.5.2 Synflorix | 53 | 1 |
| 10.5.2.1 Overview | 53 | 1 |
| 10.5.2.2 Indications | 53 | 1 |
| 10.5.2.3 Mechanism of action | 53 | 1 |
| 10.5.2.4 Dosage | 53 | 1 |
| 10.6 Vaccine Pipeline Analysis | 53 | 1 |
| 10.6.1.1 Prevnar 13 (Wyeth) | 53 | 1 |
| 11 The Future of Global Vaccines: Global Human Papillomavirus Vaccines Market | 54 | 6 |
| 11.1 Market Overview | 54 | 1 |
| 11.2 Market Forecasts | 54 | 1 |
| 11.3 Average Cost of Vaccination | 55 | 1 |
| 11.4 Target Population | 56 | 1 |
| 11.4.1 Immunization Coverage | 56 | 1 |
| 11.5 Product Analysis | 57 | 1 |
| 11.5.1 Gardasil | 57 | 1 |
| 11.5.1.1 Overview | 57 | 1 |
| 11.5.1.2 Indications | 57 | 1 |
| 11.5.1.3 Mechanism of Action | 57 | 1 |
| 11.5.1.4 Dosage | 57 | 1 |
| 11.5.2 Cervarix | 57 | 1 |
| 11.5.2.1 Overview | 57 | 1 |
| 11.5.2.2 Indications | 58 | 1 |
| 11.5.2.3 Mechanism of Action | 58 | 1 |
| 11.5.2.4 Dosage | 58 | 1 |
| 11.6 Vaccine Pipeline Analysis | 58 | 1 |
| 11.6.1 Profiles of Key Late Stage Vaccines | 58 | 1 |
| 11.6.1.1 V503 (Merck) | 58 | 1 |
| 11.6.1.2 HPV-16/18 L1/AS04 (GlaxoSmithKline) | 58 | 2 |
| 12 The Future of Global Vaccines: Global Seasonal Flu Vaccines Market | 60 | 8 |
| 12.1 Market Overview | 60 | 3 |
| 12.2 Market Forecasts | 63 | 1 |
| 12.3 Average Cost of Vaccination | 64 | 1 |
| 12.4 Target Population | 65 | 1 |
| 12.4.1 Immunization Coverage | 65 | 1 |
| 12.5 Product Analysis | 66 | 1 |
| 12.5.1 Fluzone | 66 | 1 |
| 12.5.1.1 Overview | 66 | 1 |
| 12.5.1.2 Indications | 66 | 1 |
| 12.5.1.3 Dosage | 66 | 1 |
| 12.5.2 Fluarix | 66 | 1 |
| 12.5.2.1 Overview | 66 | 1 |
| 12.5.2.2 Indications | 66 | 1 |
| 12.5.2.3 Dosage | 67 | 1 |
| 12.6 Vaccine Pipeline Analysis | 67 | 1 |
| 12.6.1 Profiles of Key Late Stage Vaccines | 67 | 1 |
| 12.6.1.1 Optaflu (Novartis) | 67 | 1 |
| 12.6.1.2 Intanza (Sanofi-Aventis) | 67 | 1 |
| 12.6.1.3 GSK2186877A | 67 | 1 |
| 13 The Future of Global Vaccines: Competitive Landscape | 68 | 9 |
| 13.1 Overview | 68 | 1 |
| 13.2 Market Share Analysis | 68 | 4 |
| 13.3 Competitor Profiles | 72 | 1 |
| 13.3.1 Sanofi Pasteur MSD | 72 | 1 |
| 13.3.2 Merck | 72 | 1 |
| GlaxoSmithKline (GSK) | 73 | 1 |
| 13.3.4 Novartis | 74 | 1 |
| 13.3.5 Pfizer | 75 | 1 |
| 13.3.6 Sanofi Pasteur | 76 | 1 |
| 14 The Future of Global Vaccines : Strategic Consolidations | 77 | 11 |
| 14.1 Mergers and Acquisitions | 77 | 2 |
| 14.1.1 Pfizer Acquires Wyeth for $68 billion | 79 | 1 |
| 14.1.2 BioSante Pharmaceuticals Acquires Cell Gensys | 79 | 1 |
| 14.1.3 Johnson &Johnson Acquires 18% Stake in Crucell | 79 | 1 |
| 14.2 Licensing Agreements | 79 | 3 |
| 14.2.1 Discovery Phase | 82 | 1 |
| 14.2.1.1 Scancell Ltd and ImmunoVaccine Technologies Inc. | 83 | 1 |
| 14.2.1.2 Regimmunue Corporation and Astellas Pharma Inc | 83 | 1 |
| 14.2.1.3 Protea Vaccine Technologies Ltd and GlaxoSmithKline Biologicals S.A | 83 | 1 |
| 14.2.2 Phase I | 83 | 1 |
| 14.2.2.1 ETEC Vaccine and Celldex Therapeutics, Inc | 83 | 1 |
| 14.2.2.2 Vical Incorporated and Naval Medical Research Center | 84 | 1 |
| 14.2.3 Phase II | 84 | 1 |
| 14.2.3.2 Novavax, Inc and Cadila Pharmaceuticals | 84 | 1 |
| 14.2.4 Phase III | 85 | 1 |
| 14.2.4.1 Immunotope Inc and ImmunoVaccine Technologies, Inc. (IVT) | 85 | 1 |
| 14.2.4.2 Nabi Biopharmaceuticals and GlaxoSmithKline (GSK) | 86 | 1 |
| 14.2.5 Filed for Approval and Approved | 86 | 1 |
| 14.2.5.1 Allergy Therapeutics and Nycomed Canada | 86 | 1 |
| 14.2.5.2 Csl Biotherapies and Merck &Co., Inc | 86 | 1 |
| 14.2.5.3 GlaxoSmithKline (GSK) and Fiocruz | 87 | 1 |
| 15 Appendix | 88 | 4 |
| 15.1 Market Definitions | 88 | 1 |
| 15.2 Key Support Data | 88 | 1 |
| 15.3 Abbreviations | 88 | 1 |
| 15.4 Methodology | 89 | 3 |
| 15.4.1 Coverage | 90 | 1 |
| 15.4.2 Secondary Research | 90 | 1 |
| 15.4.3 Primary Research | 91 | 1 |
| 15.4.4 Expert Panel Validation | 91 | 1 |
| 15.5 Contact Us | 91 | 1 |
| 15.6 Disclaimer | 91 | 1 |